SEGMENT INFORMATION (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Information about Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Segment Net Sales
United States	$	889.7	$	806.4	$	1,728.6	$	1,588.5
Europe	378.2		332.2		720.0		658.2
Japan	95.3		86.5		177.1		172.5
Rest of World	169.0		144.3		319.2		280.1
Total segment net sales	$	1,532.2	$	1,369.4	$	2,944.9	$	2,699.3
Cost of Sales
United States	$	167.5	$	146.4	$	313.5	$	286.1
Europe	84.8		74.4		167.0		148.0
Japan	13.6		12.6		25.9		24.4
Rest of World	43.9		40.3		83.7		78.7
Total segment cost of sales	$	309.8	$	273.7	$	590.1	$	537.2
Selling, general, and administrative expenses
United States	$	135.7	$	117.8	$	268.9	$	233.0
Europe	74.2		70.9		147.6		142.3
Japan	18.5		19.6		34.9		45.6
Rest of World	48.3		46.6		90.4		88.0
Total segment selling, general, and administrative expenses	$	276.7	$	254.9	$	541.8	$	508.9
Other Segment Items
United States	$	0.6	$	0.7	$	1.2	$	1.4
Europe	15.2		0.8		6.9		4.9
Japan	(0.2)		(3.6)		(4.8)		(2.9)
Rest of World	(7.9)		(3.0)		(17.1)		(4.1)
Total other segment items (a)	$	7.7	$	(5.1)	$	(13.8)	$	(0.7)
Segment Operating Income
United States	$	585.9	$	541.5	$	1,145.0	$	1,068.0
Europe	204.0		186.1		398.5		363.0
Japan	63.4		57.9		121.1		105.4
Rest of World	84.7		60.4		162.2		117.5
Total segment operating income	$	938.0	$	845.9	$	1,826.8	$	1,653.9

_______________________________________________________________________________

(a)    Other segment items include research and development expenses and foreign currency.

The table below presents a reconciliation of segment operating income to consolidated pre-tax income (in millions):

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Pre-tax Income Reconciliation
Segment operating income	$	938.0	$	845.9	$	1,826.8	$	1,653.9
Unallocated amounts:
Corporate items	(505.2)		(480.8)		(991.4)		(927.8)
Separation costs (Note 3)	(4.2)		—		(8.4)		—
Certain litigation expenses	(15.5)		(8.1)		(26.4)		(17.0)
Foreign currency	(1.9)		9.5		5.4		6.4
Consolidated operating income	411.2		366.5		806.0		715.5
Non-operating income	(11.0)		17.5		28.1		39.7
Consolidated pre-tax income	$	400.2	$	384.0	$	834.1	$	755.2

Schedule of Enterprise-Wide Information

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Net Sales by Major Product Group
Transcatheter Aortic Valve Replacement	$	1,130.9	$	1,038.6	$	2,177.5	$	2,046.5
Transcatheter Mitral and Tricuspid Therapies	134.5		83.0		249.7		155.9
Surgical Structural Heart	266.8		247.8		517.7		496.9
	$	1,532.2	$	1,369.4	$	2,944.9	$	2,699.3